ImCheck Therapeutics is driving innovation in two powerful new areas of immune system modulation: the butyrophilins superfamily of immunomodulatory molecules and gamma-delta T cells. The company is developing next generation immunotherapeutics for patients with severe unmet medical needs with a primary focus on immuno-oncology. Our growing understanding of these novel targets has also identified unique opportunities in immune-mediated inflammatory disease also known as autoimmune diseases.
ImCheck Announces Investment by BB Pureos Bioventures to Close Series B Fundraising with Total of €54 million ($64 million)
Financial & BusinessRead more
ImCheck Achieves Initial Positive Independent Safety Review and Initiates Next Stage of Phase I/IIa EVICTION Trial for ICT01 - Company Receives FDA Approval for US IND
Science & MedicineRead more